MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

Search

Apellis Pharmaceuticals Inc

Cerrado

SectorSanidad

19.53 1.72

Resumen

Variación precio

24h

Actual

Mínimo

18.85

Máximo

19.6

Métricas clave

By Trading Economics

Ingresos

-56M

-92M

Ventas

-46M

167M

Margen de beneficios

-55.292

Empleados

705

EBITDA

-56M

-80M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+86.99% upside

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-261M

2.3B

Apertura anterior

17.81

Cierre anterior

19.53

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

168 / 376 Clasificación en Healthcare

Apellis Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 jul 2025, 21:42 UTC

Adquisiciones, fusiones, absorciones

Justice Department Won't Seek Injunction for T-Mobile Acquisition of U.S. Cellular

10 jul 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Portugal Begins Process to Sell Stake in National Carrier -- Update

10 jul 2025, 17:00 UTC

Principales Movimientos del Mercado

K Wave Media Shares Drop After Convertible Note Agreement With Anson Funds

10 jul 2025, 16:31 UTC

Adquisiciones, fusiones, absorciones

Blackstone Makes $664 Million Counteroffer for Warehouse REIT Amid Bidding War -- 2nd Update

10 jul 2025, 23:47 UTC

Charlas de Mercado

Gold Edges Higher Amid Lingering Global Trade Tensions -- Market Talk

10 jul 2025, 23:40 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

10 jul 2025, 22:36 UTC

Charlas de Mercado

Tourism Holdings' Profit Warning Less Concerning Than Others -- Market Talk

10 jul 2025, 22:23 UTC

Charlas de Mercado

New Law Creates Winners and Losers Among Renewable-Energy Projects -- Market Talk

10 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

10 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

10 jul 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Toyota Tsusho America Completes Acquisition of Radius Recycling

10 jul 2025, 19:56 UTC

Charlas de Mercado

Gold Rises on Inflation Concerns -- Market Talk

10 jul 2025, 19:33 UTC

Charlas de Mercado

Oil Snaps Winning Streak As Oversupply Concerns Return -- Market Talk

10 jul 2025, 19:21 UTC

Charlas de Mercado

U.S. Natural Gas Rebound on Benign Storage Build -- Market Talk

10 jul 2025, 18:46 UTC

Charlas de Mercado

Mexican Industrial Production Seen as Mixed in May -- Market Talk

10 jul 2025, 18:15 UTC

Charlas de Mercado

Brazil's Bullish Outlook Expected to Survive Trump Tariffs -- Market Talk

10 jul 2025, 18:03 UTC

Charlas de Mercado
Ganancias

Travel Agency Investors Cautiously Optimistic After Delta Report -- Market Talk

10 jul 2025, 17:57 UTC

Charlas de Mercado

US Labor Shortage Could Weigh on Business, Economic Growth -- Market Talk

10 jul 2025, 17:34 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Conagra Falls While Simply Good Foods Adapts. What's Eating Food Companies. -- Barrons.com

10 jul 2025, 17:34 UTC

Charlas de Mercado

Canada Vows Fight Over Trump's Copper Tariffs -- Market Talk

10 jul 2025, 17:20 UTC

Charlas de Mercado

Copper Climbs as Futures Wrangle With Trump Tariff -- Market Talk

10 jul 2025, 17:20 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

10 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

10 jul 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

10 jul 2025, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

10 jul 2025, 16:02 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 jul 2025, 16:02 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

10 jul 2025, 16:02 UTC

Charlas de Mercado

Embraer Expected to Bear Brunt of U.S. Tariffs on Brazil -- Market Talk

10 jul 2025, 16:01 UTC

Adquisiciones, fusiones, absorciones

Investor AB: Advanced Instruments' Acquisition of Nova Biomedical Completed

10 jul 2025, 15:41 UTC

Charlas de Mercado

U.S. Natural Gas Storage Surplus Holds Steady -- Market Talk

Comparación entre iguales

Cambio de precio

Apellis Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

86.99% repunte

Estimación a 12 Meses

Media 35.92 USD  86.99%

Máximo 60 USD

Mínimo 17 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

10

Comprar

9

Mantener

0

Vender

Sentimiento

By Acuity

168 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.